TriNetX

Impact: TriNetX acquired key assets of Zetta Genomics, expanding its genomics data management and analytics capabilities, which enhances its ability to integrate multiomic data for clinical research and care delivery.

Impact: TriNetX acquired Cocoon to expand its leave management solutions for small and medium-sized businesses, enhancing its HR offerings with compliance-first products and AI-enabled workflows. The acquisition is not expected to materially impact TriNetX's 2026 financial guidance.

Impact: TriNetX appointed a new CEO and completed a leadership transition, positioning for growth.

Impact: TriNetX is collaborating with Regeneron Pharmaceuticals to provide secure access to its global network of de-identified health data from approximately 300 million individuals. This collaboration includes an investment of up to $200 million from Regeneron Pharmaceuticals.

Impact: TriNetX is the network from which researchers analyzed electronic health records of over 250 million patients, providing the data infrastructure for the study.

Impact: TriNetX is the global research network that provided the de-identified patient data used in the study to analyze the long-term effects of Melatonin.

Impact: TriNetX provided data for the report and its Chief People Officer commented on the findings. As an HR solutions provider for SMBs, TriNetX may benefit from increased demand for compliance and workforce management services.

Impact: TriNetX provided the multinational health database used for the study, enabling the large cohort analysis.